• Revenue down 66% to $177,564
• Net loss after tax down 56% to $514,975
• Anti-obesity project progressing, further studies planned

Anatara Lifesciences Ltd has reported its half-year results for the period ended 31 December 2025. Revenue was down 66% to $177,564, while net loss after tax decreased by 56% to $514,975. The company's anti-obesity project is progressing, with initial pre-clinical studies showing promising results for a candidate compound referred to as 'AOC'. However, the completion of the Mechanism of Action (MOA) studies was delayed slightly due to the unavailability of a specific testing kit. The company is still awaiting the full data set, which is expected to be available by late January 2026. Anatara continues to evaluate additional opportunities and strategic directions within the junior healthcare sector, while also summarizing the pre-clinical and clinical work on its GaRP project for potential publication. The company completed a successful capital raising of A$1.2 million in the December quarter of 2025 and appointed a new non-executive director, Mr Dirk Van Dissel, as part of a board renewal process.

The company remains committed to advancing the Anti-Obesity Project through its Proof-of-Concept studies and continues to assess a range of potential transactions, focusing on projects addressing areas of significant unmet medical need.